Leukemia-associated antigen (LAA)

The term **leukemia-associated antigen (LAA)** refers not to a single protein or molecule, but to a heterogeneous group of antigens that are **overexpressed or uniquely presented by malignant hematopoietic (blood-forming) cells compared to normal tissue**[1][7][3]. LAAs include proteins such as **WT1, PRAME, RHAMM, proteinase 3, hTERT, G250, BAGE, OFA-iLRP, and others** that can be recognized by the immune system, making them targets for immunotherapies such as T-cell therapies and peptide vaccinations[3][7][1][9]. Many LAAs are not fully restricted to leukemia cells and may be found on some healthy blood or non-blood tissues, so the risk of "on-target, off-tumor" toxicity is a challenge[1][5]. LAAs serve as **biomarkers** for minimal residual disease and for patient selection and monitoring in clinical trials[7]. The term “leukemia-associated antigens” is a class designation (not a unique molecular entity); for structured databases, each individual LAA (e.g., *Wilms tumor protein 1*) should be recorded separately for detailed information on their specific biological role, drug interactions, and clinical relevance. **Summary note:** *“Leukemia-associated antigens on malignant hematopoietic cells”* is **not a single molecular entity**, but a **category** encompassing multiple proteins with diverse antigenic and functional properties. It is thus not suitable as a single target entry, but its individual members (WT1, PRAME, etc.) are established therapeutic targets[1][3][7].

Other names

leukemia-associated antigenLAAs (plural)leukemia-associated peptide antigensleukemia-specific antigens (context-dependent)leukemia stem cell antigens (context-dependent)

Immune-mediated cytotoxicity - T cell–mediated lysis - Cancer vaccine–stimulated response